Research on the application effect of cognitive stimulation therapy in patients with Alzheimer’s disease based on expert consultation and semistructured interviews

• Published in: Journal of Population Therapeutics and Clinical Pharmacology
• Main Author: Shuzhen L.; Hongyan G.; Wei W.; Ruiying W.; Mulud Z.A.
• Format: Article
• Language: English
• Published: Codon Publications 2022
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142938952&doi=10.47750%2fjptcp.2022.991&partnerID=40&md5=48ea294c27078388f4c78fd6683ac191

The awareness and utilization of psychological therapies for Alzheimer’s disease have increased significantly in recent years. Limitations on the utilization of pharmacological therapy for Alzheimer’s disease in China have corresponded with this surge in greater studies in the field. For individuals who have Alzheimer’s disease, cognitive stimulation therapy (CST) is a quick self-help that is founded on the theories of quality and cognitive functioning. People with Alzheimer’s disease often participate in cognitive behav-ioral programs; however, their expense has never been studied. Being part of a meta-analysis, we analyze the application effectiveness of a CST program that is based on recent research for Alzheimer’s disease patients. A CST group therapy was given to 91 Alzheimer’s patients, who resided in healthcare settings or the general public, multiple times per week for 8 weeks; the other 70 people with Alzheimer’s disease got a medical therapy. Costs were computed, and resource utilization was tracked for 8 weeks both before and after the therapy. It was determined by a value study. In the value study, cognition and quality of life were the major and tertiary outcomes, respectively. Contours of cost-effectiveness and acceptance were drawn. It was driven based on expert consultation and semistructured interviews. In Alzheimer’s disease, CST improves intelligence and standard of living, and there was no difference in implementation expenditures between the categories. Regarding both outcome metrics, there is a significant chance that CST seems to be more expensive than conventional therapy within realistic expectations. The efficacy of CST for Alzheimer’s patients is superior to conventional treatment, and it could be the greater value. The outcomes contrast well with pharmacological studies for Alzheimer’s. Many people with Alzheimer’s disease may benefit significantly from CST groups. © 2022 Shuzhen L et al.